Select Publications

Journal articles

Caperchione CM; Stolp S; Phillips JL; Agar M; Sharp P; Liauw W; Harris CA; McCullough S; Lilian R, 2022, 'Cancer survivors’ exercise beliefs, knowledge, and behaviors: An Australian National Survey', Asia-Pacific Journal of Clinical Oncology, vol. 18, pp. 625 - 633, http://dx.doi.org/10.1111/ajco.13729

Powles T; Tomczak P; Park SH; Venugopal B; Ferguson T; Symeonides SN; Hajek J; Gurney H; Chang YH; Lee JL; Sarwar N; Thiery-Vuillemin A; Gross-Goupil M; Mahave M; Haas NB; Sawrycki P; Burgents JE; Xu L; Imai K; Quinn DI; Choueiri TK; Choueiri T; Ferguson TR; Lin TP; Symeonides SN; Haas NB; Gurney HP; Chevreau C; Burke JM; Doshi G; Melichar B; Topart D; Oudard S; Kopyltsov E; Hammers HJ; Quinn DI; Alva A; Menezes JDJ; Silva AGE; Winquist EW; Hamzaj A; Procopio G; Karaszewska B; Nowakowska-Zajdel EM; Alekseev BY; Gafanov RA; Izmailov A; Semenov A; Afanasyev SG; Lipatov ON; Powles TB; Srinivas S; McDermott D; Kochuparambil ST; Davis ID; Peltola K; Sabbatini R; Chung J; Shkolnik MI; Matveev VB; Gajate Borau P; McCune S; Hutson TE; Dri A; Sales SC; Yeung C; Alcala Castro CM; Bostrom P; Laguerre B; Buttigliero C; de Giorgi U; Fomin EA; Zakharia Y; Hwang C; Singer EA; Yorio JT; Waterhouse D; Kowalyszyn RD; Alfie MS; Yanez Ruiz E; Buchler T; Kankaanranta K; Ferretti G; Kimura G; Nishimura K; Masumori N; Tamada S; Kato H; Kitamura H; Danielewicz I; Wojcik-Tomaszewska J; Sala Gonzalez N; Chiu KY; Atkins MB; Heath E; Rojas-Uribe GA; Gonzalez Fernandez ME; Feyerabend S; Pignata S; Numakura K, 2022, 'Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet Oncology, vol. 23, pp. 1133 - 1144, http://dx.doi.org/10.1016/S1470-2045(22)00487-9

Caperchione CM; Sharp P; Phillips JL; Agar M; Liauw W; Harris CA; Marin E; McCullough S; Lilian R, 2022, 'Bridging the gap between attitudes and action: A qualitative exploration of clinician and exercise professional's perceptions to increase opportunities for exercise counselling and referral in cancer care', Patient Education and Counseling, vol. 105, pp. 2489 - 2496, http://dx.doi.org/10.1016/j.pec.2021.11.002

Wai Siu DH; O'Neill RS; Harris CA; Wang J; Ardolino L; Downton T; Tong M; Hong JH; Chin V; Clingan PR; Aghmesheh M; Soudy H, 2022, 'Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review', Immunotherapy, vol. 14, pp. 511 - 520, http://dx.doi.org/10.2217/imt-2021-0225

Kasherman L; Siu DHW; Woodford R; Harris CA, 2022, 'Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future', Cancers, vol. 14, http://dx.doi.org/10.3390/cancers14061406

Menant JC; Goldstein D; Au K; Trinh T; van Schooten KS; McCrary JM; Harris CA; Forster BC; Park SB, 2022, 'Corrigendum to “Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy” [Gait Posture 89 (2021) 178–185](S0966636221002514)(10.1016/j.gaitpost.2021.07.010)', Gait and Posture, vol. 92, pp. 1, http://dx.doi.org/10.1016/j.gaitpost.2021.11.006

Menant JC; Goldstein D; Au K; Trinh T; van Schooten KS; McCrary JM; Harris CA; Forster BC; Park SB, 2021, 'Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy', Gait and Posture, vol. 89, pp. 178 - 185, http://dx.doi.org/10.1016/j.gaitpost.2021.07.010

Gedye C; Pook DW; Krieger LEM; Harris CA; Goh JC; Kichenadasse G; Gurney H; Underhill C; Parnis F; Joshua AM; Ferguson T; Roncolato F; Harrison ML; Begbie S; Morris MF; Hovey EJ; George M; Prithviraj P; Link E; Davis ID, 2021, 'Ipilimumab plus nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab plus nivolumab in advanced non-clear cell renal cell carcinoma.', JOURNAL OF CLINICAL ONCOLOGY, vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.4565

Gedye C; Joshi AJ; Zhang AY; Martin AJ; Joshua AM; Harris CA; Underhill C; Pook DW; Toner GC; Kichenadasse G; So JY; Goh JC; Morris MF; Lawrence NJ; Ferguson T; Vasey PA; Prithviraj P; Subramaniam S; Stockler MR; Davis ID, 2021, 'Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP1601).', Journal of Clinical Oncology, vol. 39, pp. TPS367 - TPS367, http://dx.doi.org/10.1200/jco.2021.39.6_suppl.tps367

Agar M; Caperchione C; Harris C; Liauw W; Lillian R; McCullough S; Phillips J; Sharp P, 2021, 'Bridging the gap between attitudes and action: Opportunities for the cancer care workforce to support exercise counselling and referral', Journal of Science and Medicine in Sport, vol. 24, pp. S13 - S13, http://dx.doi.org/10.1016/j.jsams.2021.09.042

Siu HW; O'Neill R; Tong M; Hong J; Harris CA; Aghmesheh M; Soudy H, 2020, 'IMMUNE CHECKPOINT INHIBITOR INDUCED OVERLAPPING CARDIAC AND NEUROMUSCULAR TOXICITIES: HIGHLIGHT OF EARLY DIAGNOSIS, EARLY INITIATION OF IMMUNOSUPPRESSIVE THERAPY AND MULTIDISCIPLINARY MANAGEMENT', JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 8, pp. A178 - A179, http://dx.doi.org/10.1136/jitc-2020-SITC2020.0292

Schmidt A; Azad A; Goh J; Harris C; Joshua AM; Weickhardt A; Krieger L, 2019, 'Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options', Asia-Pacific Journal of Clinical Oncology, vol. 15, pp. 3 - 10, http://dx.doi.org/10.1111/ajco.13289

Harris CA; Daniels BJ; Ward RL; Pearson SA, 2017, 'Retrospective comparison of Australia’s Pharmaceutical Benefits Scheme claims data with prescription data in HER2 positive early breast cancer patients (2008-2012)', Public Health Research and Practice, vol. 27, http://dx.doi.org/10.17061/phrp2751744

Adelstein BA; Dobbins TA; Harris CA; Marschner IC; Ward RL, 2011, 'A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer', European Journal of Cancer, vol. 47, pp. 1343 - 1354, http://dx.doi.org/10.1016/j.ejca.2011.03.031

Harris CA; Ward RL; Dobbins TA; Drew A; Pearson S, 2011, 'The efficacy of HER2-targeted agents in metastatic breast cancer: A meta-analysis', Annals of Oncology, vol. 22, pp. 1308 - 1317, http://dx.doi.org/10.1093/annonc/mdq593

Goldstein D; Harris C; Harris C, 2010, 'Tamoxifen use in retroperitoneal fibrosis, case report and review of the literature', Internal Medicine Journal, vol. 40, pp. e5 - e7


Back to profile page